Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver [Phase 4]
Phase 4 clinical trial examining the impact of an oral anti-diabetic medication on liver fat in adults with type 2 diabetes and non-alcoholi…
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: Changing Lifestyles for Better Health [NA]
A completed clinical trial on changing lifestyles for better health in individuals with Type 2 Diabetes Mellitus; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-14Clinical Trial Update: Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita) [Phase 3]
Phase 3 trial REMIT-Sita evaluates remission outcomes with a metabolic intervention plus Sitagliptin in Type 2 Diabetes; completed with resu…
-
CLINICAL_TRIALS trial_result · 2022-03-14Clinical Trial Update: The Effects of Glycemic Optimization Before Gastric Bypass Surgery [NA]
A completed clinical trial investigating the effects of glycemic optimization before gastric bypass surgery in type 2 diabetes patients.
-
FDA approval · 2022-03-11FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for KAZANO (alogliptin and metformin hydrochloride) filed by Takeda Pharmaceuticals America, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-03-11FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for the fixed-dose combination of alogliptin and pioglitazone (alogliptin benzoate and pioglitazone …
-
FDA approval · 2022-03-11FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for alogliptin filed by Padagis Israel Pharmaceuticals Ltd, representing an additional regulator…
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus [Phase 1]
Phase 1 study assessing safety, tolerability, PK, and PD of PF-06882961 in Japanese adults with Type 2 Diabetes Mellitus completed with resu…
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003) [Phase 1]
Phase 1 trial evaluating safety and efficacy of MK-8521 versus placebo and an active diabetes drug in type 2 diabetes; study completed with …
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans [Phase 2]
Phase 2 clinical trial assessing the effect of resveratrol on age-related insulin resistance and inflammation in humans completed with resul…
-
CLINICAL_TRIALS trial_result · 2022-03-07Clinical Trial Update: A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea
Post-marketing surveillance study on NesinaAct tablet use in Korean participants with Type 2 Diabetes Mellitus has completed with results po…
-
CLINICAL_TRIALS trial_result · 2022-03-07Clinical Trial Update: To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin [Phase 3]
A Phase 3 clinical trial evaluating JT-001 add-on therapy in adults with type 2 diabetes mellitus inadequately controlled with metformin and…
-
CLINICAL_TRIALS trial_result · 2022-03-04Clinical Trial Update: Fenofibrate Versus Curcumin in Type 2 Diabetic Patients [Phase 4]
Phase 4 trial comparing fenofibrate to curcumin in adults with type 2 diabetes mellitus; study completed.
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease [Phase 2]
A Phase 2 double-blind trial evaluated BAY1142524 for efficacy, safety and tolerability in patients with type 2 diabetes and diabetic kidney…
-
FDA approval · 2022-03-02FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for STEGLUJAN, a fixed-dose combination of ertugliflozin and sitagliptin. The submission was fil…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP. [Phase 3]
Phase 3 trial evaluating the efficacy and safety of a fixed-dose combination of atorvastatin and fenofibrate versus atorvastatin alone in pa…
-
FDA approval · 2022-02-24FDA Approved: JARDIANCE — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Jardiance (empagliflozin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA approval · 2022-02-22FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original application for metformin hydrochloride extended-release tablets from ScieGen Pharmaceuticals, a generic version o…
-
CLINICAL_TRIALS research · 2022-02-15Clinical Trial Update: A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED) [Phase 3]
A Phase 3 trial evaluating whether losartan provides renal protective effects in patients with type 2 diabetes and nephropathy; the study is…
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk [Phase 3]
Phase 3 trial comparing weekly tirzepatide to daily insulin glargine in adults with type 2 diabetes and high cardiovascular risk; study comp…
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [Phase 3]
Phase 3 trial comparing tirzepatide (LY3298176) to semaglutide as add-on to metformin in type 2 diabetes completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes [Phase 3]
Phase 3 long-term safety study of tirzepatide (LY3298176) in participants with type 2 diabetes has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Post-authorization safety study evaluating empagliflozin in Type 2 diabetes patients in Saudi Arabia, focusing on ketoacidosis, severe urina…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Effect of Androgel on Type 2 Diabetic Males With Hypogonadism [Phase 4]
Phase 4 trial update on the effect of Androgel in type 2 diabetes mellitus patients with hypogonadism has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes [Phase 3]
Phase 3 trial updates comparing LY900014 to insulin lispro in adults with type 2 diabetes; results have been posted.